AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MIRM · NASDAQ · Biotechnology

Mirum Pharmaceuticals (MIRM)

Commercializes rare-disease medicines while building a broader liver and genetic-disease pipeline.

$88.04

vs last close−3.35 (−3.66%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	48	70	69	78	90	99	112	128	133	149	160	176
Cost of revenue	10	25	18	20	21	23	23	23	26	28	29	30
Gross profit	37	45	51	58	70	77	89	104	107	121	131	146
	63	77	78	82	82	101	104	109	105	125	194	188
Research & development	26	31	32	33	32	44	46	46	43	51	98	91
	37	46	46	49	51	57	58	63	62	74	96	81
Selling & marketing	0	0	0	8	0	0	0	0	0	0	0	0
General & administrative	0	0	0	41	0	0	0	0	0	0	0	81
Other expenses	0	0	0	0	0	0	0	0	0	0	0	16
Operating income	−25	−33	−26	−24	−13	−24	−15	−5	3	−5	−63	−43
	2	−3	2	0	−1	0	2	0	0	0	−727	−23
Interest income	4	4	4	3	3	3	3	3	3	3	3	4
Interest expense	4	4	4	4	4	4	4	4	4	4	4	3
Other non-operating income	−5	−1	−5	−4	−2	−3	−5	−3	0	−3	723	−24
Income before tax	−23	−35	−25	−24	−14	−24	−14	−5	3	−5	−790	−66
Income tax expense	0	0	1	1	0	−1	1	0	0	1	0	2
Net income from continuing operations	−24	−36	−25	−25	−14	−24	−15	−6	3	−6	−790	−67
Net income	−24	−36	−25	−25	−14	−24	−15	−6	3	−6	−790	−67
EPS, basic	−$0.57	−$0.71	−$0.54	−$0.52	−$0.30	−$0.49	−$0.30	−$0.12	$0.05	−$0.12	−$13.43	−$1.06
EPS, diluted	−$0.57	−$0.71	−$0.54	−$0.52	−$0.30	−$0.49	−$0.30	−$0.12	$0.05	−$0.12	−$13.43	−$1.06
Weighted average shares, basic	41	47	47	47	48	48	49	50	57	50	59	63
Weighted average shares, diluted	41	47	47	47	48	48	49	50	57	50	59	63
EBITDA	−17	−26	−15	−15	−4	−15	−4	4	9	5	−779	−11
Depreciation & amortization	3	5	6	6	6	6	6	6	6	6	7	7
EBIT	−20	−32	−21	−20	−10	−21	−10	−2	3	−1	−786	−18